Currently, Spero Therapeutics Inc [SPRO] is trading at $2.35, up 244.57%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SPRO shares have gain 245.49% over the last week, with a monthly amount glided 230.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spero Therapeutics Inc [NASDAQ: SPRO] stock has seen the most recent analyst activity on December 20, 2024, when Evercore ISI downgraded its rating to a In-line but kept the price target unchanged to $5 for it. Previously, Evercore ISI upgraded its rating to Outperform on September 23, 2022, and elevated its price target to $8. On October 01, 2021, downgrade downgraded it’s rating to Perform. H.C. Wainwright reiterated its Buy rating and increased its price target to $40 on January 22, 2021. Berenberg initiated its recommendation with a Buy and recommended $47 as its price target on December 16, 2020. In a note dated November 05, 2019, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $28 to $35.
This stock has fluctuated between a low of $0.51 and a high of $1.53 over the last 52 weeks. Spero Therapeutics Inc [NASDAQ: SPRO] shares were valued at $2.35 at the most recent close of the market.
Analyzing the SPRO fundamentals
Trailing Twelve Months sales for Spero Therapeutics Inc [NASDAQ:SPRO] were 28.30M which represents 21.57% growth. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -2.13%, Pretax Profit Margin comes in at -1.61%, and Net Profit Margin reading is -1.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.99 and Total Capital is -1.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9700 points at the first support level, and at 1.6000 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.6000, and for the 2nd resistance point, it is at 2.8600.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Spero Therapeutics Inc [NASDAQ:SPRO] is 2.56. Also, the Quick Ratio is 2.56, while the Cash Ratio stands at 1.68. Considering the valuation of this stock, the price to sales ratio is 4.64, the price to book ratio is 3.89.
Transactions by insiders
Recent insider trading involved Keutzer Timothy, Chief Operating Officer, that happened on Feb 05 ’25 when 56537.0 shares were sold. CFO & CBO, Rajavelu Esther completed a deal on Feb 05 ’25 to sell 20689.0 shares. Meanwhile, CEO & President Shukla Sath sold 0.16 million shares on Feb 05 ’25.
